Clinical Trial Update: A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efficacy, safety, and tolerability in ART-experienced adults aged 50 or older with virologic suppression who switch from BIC/FTC/TAF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIC/FTC/TAF (bictegravir/emtricitabine/tenofovir alafenamide)
• DTG/3TC (dolutegravir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV, HIV Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING